Role and regulation of VEGF and its receptors 1 and 2 in the aseptic loosening of total hip implants

Journal of Orthopaedic Research

Volumn 30, Issue 11, 2012, Pages 1830-1836

  Waris, Ville ^a,b   Sillat, Tarvo ^b,c   Waris, Eero ^c   Virkki, Liisa ^b,c   Mandelin, Jami ^c   Takagi, Michiaki ^d   Konttinen, Yrjö T ^c,e,f  

^a MIKKELI CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d YAMAGATA UNIVERSITY   (Japan)

^e ORTON ORTHOPAEDIC HOSPITAL   (Finland)

^f University of Tampere   (Finland)

Author keywords

aseptic loosening; hypoxia; osteoarthritis; total hip replacement; VEGF

Indexed keywords

CYTOKINE; INTERLEUKIN 4; PEROXIDASE; STREPTAVIDIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; FEMALE; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOLOCALIZATION; MACROPHAGE; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STAINING; STOMA; SYNOVIUM; TOTAL HIP PROSTHESIS; UPREGULATION;

AGED; ANIMALS; ANOXIA; ARTHROPLASTY, REPLACEMENT, HIP; CELL LINE; CYTOKINES; FEMALE; FIBROBLASTS; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; PROSTHESIS FAILURE; RABBITS; REOPERATION; SYNOVIAL MEMBRANE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84867233556     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22138     Document Type: Article

References (47)

1. Santavirta S, Ceponis A, Solovieva SA, et al. 1996. Periprosthetic microvasculature in loosening of total hip replacement. Arch Orthop Trauma Surg 115: 286-289.
2. Santavirta S, Xu JW, Hietanen J, et al. 1998. Activation of periprosthetic connective tissue in aseptic loosening of total hip replacements. Clin Orthop Rel Res 352: 16-24.
3. Konttinen YT, Takagi M, Mandelin J, et al. 2001. Acid attack and cathepsin K in bone resorption around total hip replacement prosthesis. J Bone Miner Res 16: 1780-1786.
4. Mandelin J, Li TF, Liljeström M, et al. 2003. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. J Bone Joint Surg (Br) 85B: 1196-1201.
5. Koreny T, Tunyogi-Csapõ M, Gál I, et al. 2006. The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. Arthritis Rheum 54: 3221-3232.
6. Dai J, Rabie AB., 2007. VEGF: an essential mediator of both angiogenesis and endochondral ossification. J Dent Res 86: 937-950.
7. Tombran-Tink J, Barnstable CJ., 2004. Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: possible mediators of angiogenesis and matrix remodeling in the bone. Biochem Biophys Res Commun 316: 573-579.
8. Miyanishi K, Trindade MC, Ma T, et al. 2003. Periprosthetic osteolysis: induction of vascular endothelial growth factor from human monocyte/macrophages by orthopaedic biomaterial particles. J Bone Miner Res 18: 1573-1583.
9. Neufeld G, Cohen T, Gengrinovitch S, et al. 1999. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22.
10. Berse B, Hunt JA, Diegel RJ, et al. 1999. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol 115: 176-182.
11. Niida S, Kaku M, Amano H, et al. 1999. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 190: 293-298.
12. Itoh H, Nasu K, Matsumoto H, et al. 2006. Hypoxia regulates vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 secretion by human oviductal epithelial cells and stromal fibroblasts. Fertil Steril 85: 1097-1102.
13. Giatromanolaki A, Sivridis E, Athanassou N, et al. 2001. The angiogenic pathway "vascular endothelial growth factor/flk-1(KDR)-receptor" in rheumatoid arthritis and osteoarthritis. J Pathol 194: 101-108.
14. Sato J, Segami N, Yoshitake Y, et al. 2003. Correlations of the expression of fibroblast growth factor-2, vascular endothelial growth factor, and their receptors with angiogenesis in synovial tissues from patients with internal derangement of the temporomandibular joint. J Dent Res 82: 272-277.
15. Jell GM, Al-Saffar N., 2001. Does a pro-angiogenic state exist in the bone-implant interface of aseptically loosened joint prosthesis ? J Mater Sci Mater Med 12: 1069-1073.
16. Spanogle JP, Miyanishi K, Ma T, et al. 2006. Comparison of VEGF-producing cells in periprosthetic osteolysis. Biomaterials 27: 3882-3887.
17. Kranenburg AR, de Boer WI, Alagappan VK, et al. 2005. Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease. Thorax 60: 106-113.
18. Clauss M., 2000. Molecular biology of the VEGF and the VEGF receptor family. Semin Thromb Hemost 26: 561-569.
19. Ferrara N, Gerber HP, LeCouter J., 2003. The biology of VEGF and its receptors. Nat Med 9: 669-676.
20. Knowles HJ, Athanasou NA., 2009. Canonical and non-canonical pathways of osteoclast formation. Histol Histopathol 24: 337-346.
21. Deckers MM, van Bezooijen RL, van der Horst G, et al. 2002. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 143: 1545-1553.
22. Yeh LC, Lee JC., 1999. Osteogenic protein-1 increases gene expression of vascular endothelial growth factor in primary cultures of fetal rat calvaria cells. Mol Cell Endocrinol 153: 113-124.
23. Konttinen YT, Waris V, Xu JW, et al. 1997. Transforming growth factor-beta 1 and 2 in the synovial-like interface membrane between implant and bone in loosening of total hip arthroplasty. J Rheumatol 24: 694-701.
24. Purdue PE, Koulouvaris P, Potter HG, et al. 2007. The cellular and molecular biology of periprosthetic osteolysis. Clin Orthop Relat Res 454: 251-261.
25. Takei I, Takagi M, Santavirta S, et al. 1999. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in joint fluid of the patients with loose artificial hip joints. J Biomed Mater Res 45: 175-183.
26. Waris V, Xu JW, Nordsletten L, et al. 1996. Basic fibroblast growth factor (bFGF) in the synovial-like membrane around loose total hip prostheses. Scand J Rheumatol 25: 257-262.
27. Waris V, Zhao DS, Leminen H, et al. 2004. Insulin-like growth factors I and II in the aseptic loosening of total hip implants. Scand J Rheumatol 33: 428-431.
28. Waris V, Waris E, Sillat T, et al. 2010. BMPs in periprosthetic tissues around aseptically loosened total hip implants. Acta Orthop 81: 420-426.
29. Xu JW, Konttinen YT., Li TF, et al. 1998. Production of platelet-derived growth factor in aseptic loosening of total hip replacement. Rheumatol Int 17: 215-221.
30. Santavirta S, Pajamäki J, Eskola A, et al. 1991. Proliferative cell response to the loosening of THR. A cytofluorographic cell cycle analysis. Arch Orthop Trauma Surg 111: 43-46.
31. Mandelin J, Li TF, Hukkanen M, et al. 2005. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kB ligand, osteoprotegerin, and cathepsin K. J Rheumatol 32: 713-720.
32. Santavirta S, Konttinen YT, Bergroth V, et al. 1990. Aggressive granulomatous lesions associated with hip arthroplasty. Immunopathological studies. J Bone Joint Surg (Am) 72A: 252-258.
33. Santavirta S, Hoikka V, Eskola A, et al. 1990. Aggressive granulomatous lesions in cementless total hip arthroplasty. J Bone Joint Surg (Br) 72B: 980-984.
34. Konttinen YT, Nykänen P, Nordström D, et al. 1989. DNA synthesis in prolyl 4-hydroxylase positive fibroblasts in situ in synovial tissue. An autoradiography-immunoperoxidase double labeling study. J Rheumatol 16: 339-345.
35. Čeponis A, Konttinen YT, Mackevičius Z, et al. 1996. Aberrant vascularity and von Willebrand factor distribution in inflamed synovial membrane. J Rheumatol 23: 1880-1886.
36. Ng CT, Biniecka M, Kennedy A, et al. 2010. Synovial tissue hypoxia and inflammation in vivo. Ann Rheum Dis 69: 1389-1395.
37. Konttinen YT, Saari H, Santavirta S, et al. 1988. Synovial fibroblasts. Scand J Rheumatol Suppl 76: 95-103.
38. Konttinen YT, Li TF, Hukkanen M, et al. 2000. Signals targeting the synovial fibroblast in arthritis. Arthritis Res 2: 348-355.
39. Tunyogi-Csapo M, Koreny T, Vermes C, et al. 2007. Role of fibroblasts and fibroblast-derived growth factors in periprosthetic angiogenesis. J Orthop Res 25: 1378-1388.
40. Barrientos S, Stojadinovic O, Golinko MS, et al. 2008. Growth factors and cytokines in wound healing. Wound Repair Regen 16: 585-601.
41. Matsumoto Y, Tanaka K, Hirata G, et al. 2002. Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints. J Immunol 168: 5824-5831.
42. Nakagawa M, Kaneda T, Arakawa T, et al. 2000. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 473: 161-164.
43. Jackson JR, Minton JA, Ho ML, et al. 1997. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. J Rheumatol 24: 1253-1259.
44. Loria MP, Dambra P, Moretti B, et al. 2004. Role of cytokines in gonarthrosis and knee prosthesis aseptic loosening. J Orthop Sci 9: 274-279.
45. Arora A, Song Y, Chun L, et al. 2003. The role of the TH1 and TH2 immune responses in loosening and osteolysis of cemented total hip replacements. J Biomed Mater Res A 64: 693-697.
46. Brown MA, Pierce JH, Watson CJ, et al. 1987. B cell stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cells. Cell 50: 809-818.
47. Solovieva SA, Ceponis A, Konttinen YT, et al. 1996. Mast cells in loosening of totally replaced hips. Clin Orthop Relat Res 322: 158-165.